(688506)“SICHUAN BIOKIN PHARMACEUTICAL CO., LTD.”Announcement on Voluntary Disclosure of Acceptance of the Marketing Application for iza-bren (EGFR×HER3 dual-antibody ADC) for the Treatment of Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
Attachments
688506_20260121_L348.pdf
